News
Zacks.com on MSN
Will GSK Be Able to Resolve Its Vaccine Challenges Anytime Soon?
GSK faces U.S. vaccine sales declines as Shingrix and Arexvy stumble. Penmenvy approval and pipeline efforts may aid long-term growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback